The patent relates to humanized antibodies that recognize human IL-23p19 and modulate its activity, particularly in inflammatory, autoimmune and proliferative disorders.
The case is interesting as it deals with the exercise of discretion by the OD when not- admitting late filed submissions of the opponent.
Brief outline of the procedure
The patent was revoked for lack of sufficiency by the OD.